Primary mediastinal large B-cell lymphoma
Primary mediastinal large B-cell lymphoma
Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct clinical and biological disease from other types of DLBCL. It is more frequent in young female and constitutes 6%-10% of all DLBCL. PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis. Molecular analysis shows it to be a distinct entity from other DLBCL. Rituximab CHOP/MACOP-B-like regimens followed by mediastinal radiotherapy (RT) were associated with a 5-years PFS of 75%-85%. More intensive regimens, as DA-EPOCH-R without mediastinal RT, have shown very promising results, but this therapeutic advance needs to be confirmed in further prospective trials. The role of consolidative mediastinal RT should be still better assess in prospective comparative studies. PET-CT scan is a powerful tool to define the real quality of response and it is hoped that future prospective trials may allow its role in the de-escalation of mediastinal RT.
Journal Article, Review
318-327
Martelli, Maurizio
32f72970-6db0-45ec-9246-6d074b504192
Ferreri, Andrés
81ff6bc3-49c1-4480-9bb5-0198cfda8f6e
Di Rocco, Alice
39899c86-ad50-40cd-be74-290e64df1cd2
Ansuinelli, Michela
ec1c5189-72e3-4dad-8d48-b8efee1f3cc7
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
May 2017
Martelli, Maurizio
32f72970-6db0-45ec-9246-6d074b504192
Ferreri, Andrés
81ff6bc3-49c1-4480-9bb5-0198cfda8f6e
Di Rocco, Alice
39899c86-ad50-40cd-be74-290e64df1cd2
Ansuinelli, Michela
ec1c5189-72e3-4dad-8d48-b8efee1f3cc7
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Martelli, Maurizio, Ferreri, Andrés, Di Rocco, Alice, Ansuinelli, Michela and Johnson, Peter W.M.
(2017)
Primary mediastinal large B-cell lymphoma.
Critical Reviews in Oncology/Hematology, 113, .
(doi:10.1016/j.critrevonc.2017.01.009).
Abstract
Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct clinical and biological disease from other types of DLBCL. It is more frequent in young female and constitutes 6%-10% of all DLBCL. PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis. Molecular analysis shows it to be a distinct entity from other DLBCL. Rituximab CHOP/MACOP-B-like regimens followed by mediastinal radiotherapy (RT) were associated with a 5-years PFS of 75%-85%. More intensive regimens, as DA-EPOCH-R without mediastinal RT, have shown very promising results, but this therapeutic advance needs to be confirmed in further prospective trials. The role of consolidative mediastinal RT should be still better assess in prospective comparative studies. PET-CT scan is a powerful tool to define the real quality of response and it is hoped that future prospective trials may allow its role in the de-escalation of mediastinal RT.
This record has no associated files available for download.
More information
Accepted/In Press date: 14 January 2017
e-pub ahead of print date: 21 January 2017
Published date: May 2017
Keywords:
Journal Article, Review
Identifiers
Local EPrints ID: 414472
URI: http://eprints.soton.ac.uk/id/eprint/414472
ISSN: 1040-8428
PURE UUID: aceb427a-403e-4493-8f83-9c0f9632a99e
Catalogue record
Date deposited: 29 Sep 2017 16:31
Last modified: 16 Mar 2024 03:00
Export record
Altmetrics
Contributors
Author:
Maurizio Martelli
Author:
Andrés Ferreri
Author:
Alice Di Rocco
Author:
Michela Ansuinelli
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
